Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

Journal article

A dose-dependent superiority on glycaemic efficacy and body weight reduction was evident with tirzepatide vs placebo, GLP-1 RAs and basal insulin. Tirzepatide did not increase the odds of hypoglycaemia but was associated with increased incidence of gastrointestinal adverse events. Study limitations include presence of statistical heterogeneity in the meta-analyses for change in HbA_1c and body weight, assessment of risk of bias solely for the primary outcome, and generalisation of findings mainly to individuals who are overweight or obese and already on metformin-based background therapy. PROSPERO registration no. CRD42021283449.

Authors: Karagiannis, T; Avgerinos, I; Liakos, A; Del Prato, S; Matthews, DR

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer
• Journal: Diabetologia
• Volume: 65
• Issue: 8
• Pages: 1251-1261
• Publication date: 2022-05-17
• DOI: 10.1007/s00125-022-05715-4
• EISSN: 1432-0428
• ISSN: 0012-186X
• Language: English
• Keywords: Clinical trial; Gastroenterology; Medicine; Adverse effect; Glucagon-like peptide 1 receptor; Internal medicine; Receptor; Endocrinology; Exenatide; Diabetes mellitus; Placebo; Type 2 diabetes; Discontinuation; Meta-analysis; Agonist